Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 1Breast 1

Conditions

Pancreatic Neoplasms 3Mesothelioma 3Neoplasms 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thymoma 1Ovarian Neoplasms 1Mesothelioma, Malignant 1Medical Oncology 1Fallopian Tube Endometrioid Adenocarcinoma 1Cholangiocarcinoma 1Adenocarcinoma of Lung 1

Interventions

Gemcitabine 679130-nm albumin-bound paclitaxel 198Fluorouracil 186Oxaliplatin 175Albumin-Bound Paclitaxel 151Capecitabine 137Leucovorin 131Irinotecan 113Radiotherapy 95Taxes 83pembrolizumab 80Cisplatin 72Erlotinib Hydrochloride 69Radiosurgery 67Nivolumab 56Bevacizumab 54Drug Therapy 52Cyclophosphamide 49Magnetic Resonance Spectroscopy 46folfirinox 42Docetaxel 41Cetuximab 40Specimen Handling 37irinotecan sucrosofate 36S 1 (combination) 36Biopsy 31Radiation 29Paclitaxel 29Ipilimumab 27durvalumab 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Pancreatic Neoplasms × anetumab ravtansine × Clear all
NCT03816358 2026-05-13

Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
Gastrointestinal

Pancreatic Neoplasms

NCT03102320 2022-06-30

ARCS-Multi

Bayer

Phase 1 Completed
173 enrolled
BreastGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms, Pancreatic Neoplasms, Thymoma, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT03023722 2021-10-28

Phase II Anetumab Ravtansine in Pre-treated Mesothelin-expressing Pancreatic Cancer

Yale University

Phase 2 Completed
18 enrolled 10 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡